TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2010 - 2026)
TherapeuticsMD (TXMD) posted Depreciation & Amortization (CF) of $94000.0 for Q1 2026, down 3.09% on a QoQ basis from $97000.0 in Q4 2025, and down 1.05% year-over-year from $95000.0 in Q1 2025.
TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
TherapeuticsMD's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $94000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 1.05% year-over-year to $94000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383000.0 (down 18.68% YoY) and the FY2025 annual result came in at $384000.0, down 24.56% from the prior year.
- Depreciation & Amortization (CF) was $94000.0 for Q1 2026 at TherapeuticsMD, down from $97000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $637000.0 in Q4 2023 and bottomed at $27000.0 in Q1 2023.
- A 5-year average of $182529.4 and a median of $129000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) plunged 91.79% — and 2024, when it surged 392.59%.
- TherapeuticsMD's Depreciation & Amortization (CF) stood at $309000.0 in 2022, then surged by 106.15% to $637000.0 in 2023, then tumbled by 84.3% to $100000.0 in 2024, then declined by 3.0% to $97000.0 in 2025, then slipped by 3.09% to $94000.0 in 2026.
- Business Quant data shows TXMD's Depreciation & Amortization (CF) at $94000.0 in Q1 2026, $97000.0 in Q4 2025, and $96000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | 94,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94,000.00 |
| Mar 31, 2026 | 94,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Mar 31, 2025 | 95,000.00 |
| Mar 31, 2025 | 95,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Mar 31, 2024 | 133,000.00 |
| Mar 31, 2024 | 133,000.00 |
| Dec 31, 2023 | 637,000.00 |
| Dec 31, 2023 | 637,000.00 |